The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000703303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/03/2026
Date registered
Help: Date registered
12/06/2026
Date last updated
Help: Date last updated
12/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Pilot Randomised Clinical Trial of best practice wound management practice using OPAL X cream or standard moisturising creams in residential aged care facilities
Scientific title
Testing the feasibility of cluster randomised controlled trial of best practice wound care using OPAL X wound healing cream, compared with best practice wound care using standard moisturiser for wounds in people living in residential care facilities.
Additional trial identifiers [1] 316706 0
00000
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
skin tears 341328 0
skin ulcers 341664 0
Quality of undamaged skin, and resistance to new skin tears after 12 weeks of regular use 342099 0
Condition category
Condition code
Skin 337398 337398 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Use of a commercially developed skin product - OPAL X to be applied on the skin around wound at change of wound dressing to a width of 2cm around the edge of the wound and rubbed in to the skin until no excess is left on the skin. The dose will vary depending on the size of the wound. For a lesion 5 cm in diameter the dose will be approximately 1/2 a fingertip unit (FTU)

The cream will be applied at each dressing change until the wound is healed, or up to 12 weeks, whichever is the lesser. In addition, it will be applied twice daily to the affected limb for 12 weeks after the onset of treatment. (Testing the objectives of 1) whether OPAL X reduces the incidence of new skin tears compared with standard skin moisturising creams; and 2) whether regular use of OPAL X improves underlying skin quality compared with regular use of standard moisturising creams.)

Adherence is being monitored via a form devised for the trial to be completed with each dressing change,

OPAL applied to the whole affected limb twice daily for the duration of wound care until wound healing (normal best practice for wounds of any type).. Unused creams will be returned to the study manager at the end of 12 weeks,
Intervention code [1] 333618 0
Treatment: Drugs
Description of the comparator or control
Standard moisturising cream is to be used as a moisturiser as part of best wound management practice for skin tears and chronic ulcers from any condition. Standard skin creams are to be supplied by each participating Aged care facility. This is standard practice and provided as part of normal service in aged care facilities.
Control group
Active

Outcomes
Primary outcome [1] 344916 0
Assess feasibility of a full trial using cluster randomisation of aged care facilities.
Timepoint [1] 344916 0
Interviews and questionnaires about the feasibility of the trial will occur at trial end. That is: after all residents who were involved in the trial have finished both the treatment to wound healing, and 12 weeks of OPAL X or standard moisturising cream applied to the affected limb.
Secondary outcome [1] 459747 0
Time from acute skin tear to full healing
Timepoint [1] 459747 0
Measurements taken weekly from baseline to week 4, or until wound is fully healed. If the wound persists at four weeks, then four weekly thereafter until trial completion at 12 weeks after treatment started or till full wound healing is achieved.
Secondary outcome [2] 459748 0
For Chronic wounds - eg skin ulcers: Time to healing. Or, if not healed at 12 weeks, Percentage change in wound surface area from baseline to 12 weeks after treatment commenced..
Timepoint [2] 459748 0
Time to full healing. If not fully healed by 12 weeks, percentage reduction in surface area from baseline.
Secondary outcome [3] 459749 0
Change in skin quality
Timepoint [3] 459749 0
12 weeks from commencement of treatment.
Secondary outcome [4] 462258 0
Number of new skin wounds on the index limb in the 12 weeks after treatment commenced.
Timepoint [4] 462258 0
12 weeks post commencement of treatment.

Eligibility
Key inclusion criteria
All residents of each aged care facility not excluded (see below) will be recruited to the study. Only those who develop an acute wound during the first two months, or those who come in to the study ( ie- pre-existing acute or chronic wounds) will be treated,

The reason for this is to ensure that wound management is started promptly after the wound occurs, and not delayed by the process of achieving informed consent from either the resident themselves or their Enduring Guardian.

Minimum age
60 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Allergies to papaya pulp, skin or seeds
2. Severe, active peripheral vascular disease
3. end stage heart failure
4. Taking warfarin or second generation anticoagulant medicines (Direct anticoagulant therapy or non-potassium anticoagulant therapy)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Cluster randomised trial design at the level of participating aged care facilities
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomisation
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Other
Other design features
Cluster randomisation of five aged care facilities Three facilities will be randomised to the active arm and two the placebo arm.
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
For primary outcome measures:
qualitative analysis of questionnaire responses
semistructured interviews of of key stakeholders

For secondary outcomes - appropriate methods of change in continuous variables based on parametric or nonparametric distribution of results.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
TAS

Funding & Sponsors
Funding source category [1] 321311 0
Commercial sector/Industry
Name [1] 321311 0
OPAL X Therapeutics Pty Ltd
Country [1] 321311 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
OPAL X Therapeutics Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324042 0
None
Name [1] 324042 0
Address [1] 324042 0
Country [1] 324042 0
Other collaborator category [1] 283886 0
Other
Name [1] 283886 0
Uniting AgeWell group (Provisional approval at present)
Address [1] 283886 0
Country [1] 283886 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319844 0
University of Tasmania Human Research Ethics Committee
Ethics committee address [1] 319844 0
Ethics committee country [1] 319844 0
Australia
Date submitted for ethics approval [1] 319844 0
08/03/2026
Approval date [1] 319844 0
03/06/2026
Ethics approval number [1] 319844 0
H40443

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148590 0
Prof Geoffrey Mitchell
Address 148590 0
c/- OPAL X Therapeutics Pty Ltd, Suite 5, 531 Hay St, Subiaco, WA, 6008
Country 148590 0
Australia
Phone 148590 0
+61 0412775117
Fax 148590 0
Email 148590 0
Contact person for public queries
Name 148591 0
Geoffrey Mitchell
Address 148591 0
c/- OPAL X therapeutics Pty Ltd, Suite 5, 531 Hay St, Subiaco, WA, 6008
Country 148591 0
Australia
Phone 148591 0
+61 0412775117
Fax 148591 0
Email 148591 0
Contact person for scientific queries
Name 148592 0
Prof Geoff Mitchell
Address 148592 0
OPAL X Therapeutics Pty Ltd, Suite 5, 531 Hay St, Subiaco, WA, 6008
Country 148592 0
Australia
Phone 148592 0
+61 0412775117
Fax 148592 0
Email 148592 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Commercial in confidence



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.